2026-08-05T13:43:57Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/88502025-03-04T18:09:02Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16978

00925njm 22002777a 4500 dc Vigon-Hernandez, Lorena author Vázquez-Morón, Sonia author Berenguer, Juan author González-García, Juan author Jimenez-Sousa, Maria Angeles author Guardiola, Josep M author Crespo, Manuel author de Los Santos, Ignacio author Von Wichmann, Miguel A author Carrero, Ana author Yélamos, María Belén author Gómez, Julián author Resino, Salvador author Martinez, Isidoro author GESIDA 3603b Cohort Study Group author 2019-08-21 The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR. Sci Rep. 2019 Aug 21;9(1):12163. 10.1038/s41598-019-48592-5 2045-2322 2045-2322 Scientific reports 31434968 http://hdl.handle.net/20.500.12105/8850 Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR